Goldman Sachs raised the firm’s price target on Ideaya Biosciences (IDYA) to $30 from $27 and keeps a Neutral rating on the shares. New data for Ideaya’s darovasertib in first-line metastatic uveal melanoma showed median overall survival of 21.1 months, exceeding base expectations of 18-21 months and likely driving stock outperformance, the analyst tells investors in a resarch note. The results support optimism for the ongoing Phase 2/3 trial ahead of 2026 progression free survival data, though uncertainty remains regarding outcomes in the HLA-A2 negative subgroup, Goldman says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $41 from $38 at RBC Capital
- Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
- IDEAYA Biosciences Presents Promising Phase 2 Data
- IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating
- Ideaya Biosciences presents clinical data from OptimUM-09 trial